MYELOFIBROSIS (MF)
Clinical trials for MYELOFIBROSIS (MF) explained in plain language.
Never miss a new study
Get alerted when new MYELOFIBROSIS (MF) trials appear
Sign up with your email to follow new studies for MYELOFIBROSIS (MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to shrink enlarged spleens in bone marrow cancer
Disease control CompletedThis study tests whether adding the experimental drug navitoclax to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 252 adults with myelofibrosis took part. The main goal was to see if the combo …
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 17, 2026 09:24 UTC
-
New pill shows promise for rare blood cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug, flonoltinib maleate, in 31 people with myeloproliferative neoplasms (MPNs), a group of bone marrow disorders that can lead to serious complications. The main goals were to check the drug's safety and find the best dose. Researchers also l…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for rare bone marrow cancer: drug combo shrinks spleens
Disease control CompletedThis study tested a drug called navitoclax, either alone or added to the standard treatment ruxolitinib, in 191 people with myelofibrosis, a rare bone marrow cancer. The main goal was to see if the treatment could shrink the spleen by at least 35% after 24 weeks. The study also l…
Matched conditions: MYELOFIBROSIS (MF)
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:41 UTC